APA (7th ed.) Citation

Wilbraham, D., Biglan, K. M., Svensson, K. A., Tsai, M., Pugh, M., Ardayfio, P., & Kielbasa, W. (2022). Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease. Clinical pharmacology in drug development, 11(3), 324-332. https://doi.org/10.1002/cpdd.1039.

Chicago Style (17th ed.) Citation

Wilbraham, Darren, Kevin M. Biglan, Kjell A. Svensson, Max Tsai, Melissa Pugh, Paul Ardayfio, and William Kielbasa. "Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease." Clinical Pharmacology in Drug Development 11, no. 3 (2022): 324-332. https://doi.org/10.1002/cpdd.1039..

MLA (9th ed.) Citation

Wilbraham, Darren, et al. "Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease." Clinical Pharmacology in Drug Development, vol. 11, no. 3, 2022, pp. 324-332, https://doi.org/10.1002/cpdd.1039..